Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Attovia Therapeutics, Inc.

NASDAQ: ATTO · Life Sciences · 2 alerts · CIK 2058707

Share price
$14.73Close, Nov 16
Market cap
$672M
Shares outstanding
45.65MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Attovia Therapeutics, Inc. filings on SEC EDGAR ↗

4:16 PM ET 10-Q
Financial Results

Attovia Therapeutics Q3 2026 Results: Net Loss of $22.3M, Loss Widens

Attovia Therapeutics is an emerging growth company focused on developing product candidates ATTO-1310, ATTO-2306, and ATTO-1091 for inflammatory and pruritic diseases. As of October 31, 2026, the company had 45,712,536 shares of common stock outstanding and continues to incur significant operating losses with no product revenue generated to date.

Key figure
Net loss $22.3M
4:11 PM ET 8-K
Clinical Trial Data

Attovia Therapeutics Clinical Trial Data

Attovia Therapeutics announced positive topline 12-week results from its Phase 1b study of ATTO-1310 in patients with chronic pruritus and high-itch atopic dermatitis. The data showed rapid and sustained itch relief with 82% of chronic pruritus patients achieving a clinically meaningful reduction in itch at Week 12, supporting the potential for quarterly maintenance dosing.

“The recently announced 12-week topline results from our ATTO-1310 Phase 1b trial exceeded our expectations, building on the compelling Week 4 findings and providing further evidence supporting our differentiated target product profile: rapid, deep, and durable itch relief, meaningful skin lesion improvements, the potential for quarterly dosing, and a favorable safety profile.”

Tao Fu, Founder and Chief Executive Officer of Attovia

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.